POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF AUTOIMMUNE DISORDERS
First Claim
Patent Images
1. A method for treating a mammal in need of treatment thereof for an autoimmune disease, comprising administering to the mammal an inhibitor of the TNF (tumor necrosis factor) pathway to treat the autoimmune disease;
- if manifestation of the autoimmune disease in the subject is not at least ameliorated by administering the inhibitor of the TNF pathway, administering an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;
6-41, to treat the autoimmune disease.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention, in at least some embodiments, relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders and including for inducing tolerance to a specific antigen.
-
Citations
32 Claims
-
1. A method for treating a mammal in need of treatment thereof for an autoimmune disease, comprising administering to the mammal an inhibitor of the TNF (tumor necrosis factor) pathway to treat the autoimmune disease;
- if manifestation of the autoimmune disease in the subject is not at least ameliorated by administering the inhibitor of the TNF pathway, administering an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;
6-41, to treat the autoimmune disease. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- if manifestation of the autoimmune disease in the subject is not at least ameliorated by administering the inhibitor of the TNF pathway, administering an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;
-
19. A method for treating a mammal in need of treatment for rheumatoid arthritis, comprising determining that the mammal did not respond to a previous rheumatoid arthritis treatment;
- and administering to the mammal an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;
26 or 43 in a dosage in a range of from 10-15 mg/kg of a weight of the mammal. - View Dependent Claims (20, 21, 22, 23, 24, 25)
- and administering to the mammal an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;
-
26. A method for treating a mammal in need of treatment thereof for an autoimmune disease, comprising administering to the mammal an inhibitor of the TNF pathway to treat the autoimmune disease;
- determining that manifestation of the autoimmune disease in the subject is at least ameliorated by administering the inhibitor of the TNF pathway;
after a period of time has relapsed, determining that expression of the autoimmune disease in the subject is no longer at least ameliorated by administering the inhibitor of the TNF pathway; and
administering an isolated polypeptide comprising a protein having an amino acid sequence according to any of SEQ ID NOs;
6-41, to treat the autoimmune disease. - View Dependent Claims (27, 28, 29, 30, 31, 32)
- determining that manifestation of the autoimmune disease in the subject is at least ameliorated by administering the inhibitor of the TNF pathway;
Specification